Variables Impacting Silicone Oil Migration and Biologics in Prefilled Syringes.

ICP-MS MFI Prefilled syringes (PFS) Protein formulation RMM Silicone oil migration Siliconization process Surfactants Syringe functionality Syringe manufacturer

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
08 2023
Historique:
received: 10 03 2023
revised: 20 05 2023
accepted: 21 05 2023
medline: 17 7 2023
pubmed: 28 5 2023
entrez: 27 5 2023
Statut: ppublish

Résumé

Prefilled syringes (PFS) as a primary container for parenteral drug products offer significant advantages, such as fast delivery time, ease of self-administration and fewer dosing errors. Despite the benefits that PFS can provide to patients, the silicone oil pre-coated on the glass barrels has shown migration into the drug product, which can impact particle formation and syringe functionality. Health authorities have urged product developers to better understand the susceptibility of drug products to particle formation in PFS due to silicone oil. In the market, there are multiple syringe sources provided by various PFS suppliers. Due to current supply chain shortages and procurement preferences for commercial products, the PFS source may change in the middle of development. Additionally, health authorities require establishing source duality. Therefore, it is crucial to understand how different syringe sources and formulation compositions impact the drug product quality. Here, several design of experiments (DOE) are executed that focus on the risk of silicone oil migration induced by syringe sources, surfactants, protein types, stress, etc. We utilized Resonant Mass Measurement (RMM) and Micro Flow Imaging (MFI) to characterize silicone oil and proteinaceous particle distribution in both micron and submicron size ranges, as well as ICP-MS to quantify silicon content. The protein aggregation and PFS functionality were also monitored in the stability study. The results show that silicone oil migration is impacted more by syringe source, siliconization process and surfactant (type & concentration). The break loose force and extrusion force across all syringe sources increase significantly as protein concentration and storage temperature increase. Protein stability is found to be impacted by its molecular properties and is less impacted by the presence of silicone oil, which is the same inference drawn in other literatures. A detailed evaluation described in this paper enables a thorough and optimal selection of primary container closure and de-risks the impact of silicone oil on drug product stability.

Identifiants

pubmed: 37244516
pii: S0022-3549(23)00204-6
doi: 10.1016/j.xphs.2023.05.017
pii:
doi:

Substances chimiques

Silicone Oils 0
Biological Products 0
Pharmaceutical Preparations 0
Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2203-2211

Informations de copyright

Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Kayla Gentile (K)

Analytical Enabling Capabilities, Analytical Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Chengbin Huang (C)

Analytical Enabling Capabilities, Analytical Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Xiaoyang Liu (X)

Analytical Enabling Capabilities, Analytical Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Laurence Whitty-Léveillé (L)

Analytical Enabling Capabilities, Analytical Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Hassen Hamzaoui (H)

Device Development, Pharmaceutical Sciences & Clinical Supply Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ,07065, USA.

Eduardo Cristofolli (E)

Device Development, Pharmaceutical Sciences & Clinical Supply Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ,07065, USA.

William Rayfield (W)

Bioprocess Downstream Platform Development, Bioprocess Research & Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Nelson Lee Afanador (NL)

Biostatistics, Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA, 19486, USA.

Sarita Mittal (S)

Analytical Enabling Capabilities, Analytical Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Yogita Krishnamachari (Y)

Sterile and Specialty Products, Pharmaceutical Sciences & Clinical Supply, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Hanmi Xi (H)

Analytical Enabling Capabilities, Analytical Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA.

Xi Zhao (X)

Analytical Enabling Capabilities, Analytical Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA; Sterile and Specialty Products, Pharmaceutical Sciences & Clinical Supply, Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ, 07033, USA. Electronic address: xi.zhao1@merck.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH